Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Everest Medicines Ltd. ( (HK:1952) ) has provided an update.
Everest Medicines Ltd. has announced that its board of directors will meet on March 25, 2025, to consider and approve the company’s annual results for the year ending December 31, 2024. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders and the company’s market positioning.
More about Everest Medicines Ltd.
Everest Medicines Ltd. is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products. The company operates primarily in the healthcare industry, targeting unmet medical needs in the Asian markets.
YTD Price Performance: -7.44%
Average Trading Volume: 5,599,413
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$14.63B
For a thorough assessment of 1952 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue